CD274 and neoplasm: OS was 69.2% (95% CI: 64.1–73.8) in the pembrolizumab-combination group versus 49.4% (95% CI: 42.1–56.2) in the placebo-combination group (p < 0.001), regardless of PD-L1 tumor expression status.